Loading
Led MURANO, which established venetoclax plus rituximab as fixed-duration therapy for relapsed CLL.
John Seymour was principal investigator of MURANO, the trial showing two years of venetoclax plus rituximab dramatically improves progression-free and overall survival compared with bendamustine-rituximab in relapsed CLL, the first randomised proof of venetoclax's benefit and the first fixed-duration targeted regimen. He co-led the first-in-human venetoclax studies with the Melbourne group that discovered BCL2 inhibition and leads haematology at Peter Mac.
Shares BCL-2, CD20, Venetoclax, MRD / molecular residual disease testing and the tags cll, venetoclax.
Shares BCL-2, CD20, Venetoclax, MRD / molecular residual disease testing and the tags cll, venetoclax.
Shares Peter MacCallum Cancer Centre, BCL-2, Venetoclax, MRD / molecular residual disease testing and the tags venetoclax, australia.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tag cll.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia and the tags cll, australia.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tag cll.
Shares BCL-2, CD20, Venetoclax, Chronic lymphocytic leukaemia.
Shares Peter MacCallum Cancer Centre, CD20 and the tag australia.